Nemaura Medical Inc. (NMRD) Stock Analysis

Nemaura Medical Inc. (NMRD) Healthcare & Pipeline Overview

Nemaura Medical Inc. develops and manufactures the sugarBEAT non-invasive continuous glucose monitoring (CGM) system, targeting individuals with Type I and Type II diabetes and pre-diabetic patients. The company's focus on non-invasive technology differentiates it in the competitive medical device market, offering a potential alternative to traditional CGM methods.

What Is the Investment Thesis for NMRD?

Nemaura Medical Inc. presents a notable research candidate within the medical device sector, driven by the increasing prevalence of diabetes and the demand for non-invasive glucose monitoring solutions. The company's sugarBEAT product offers a potential alternative to traditional CGM systems, appealing to patients seeking a more convenient and painless monitoring experience. Key value drivers include the expansion of sugarBEAT's market reach, regulatory approvals in key geographies, and the successful implementation of diabetes prevention and reversal programs. However, investors may want to evaluate the company's limited financial resources, reliance on regulatory approvals, and competition from established players in the CGM market. The company's beta of -117.34 indicates high volatility.

Based on FMP financials and quantitative analysis

NMRD Key Highlights

Nemaura Medical Inc. focuses on non-invasive continuous glucose monitoring (CGM) technology.

• The company's primary product is sugarBEAT, a non-invasive CGM device.
• Nemaura Medical also offers proBEAT, a wellness guidance program.
• The company targets individuals with Type I and Type II diabetes, as well as pre-diabetic patients.
• Nemaura Medical Inc. was founded in 2009 and is based in New York.

Who Are NMRD's Competitors?

NMRD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NMRD's Key Strengths?

Non-invasive CGM technology.

• Focus on diabetes prevention and reversal.
• Wellness guidance program (proBEAT).
• Established presence in the US market.

What Are NMRD's Weaknesses?

Limited financial resources.

• Reliance on regulatory approvals.
• Competition from established players.
• Small employee count (36).

What Could Drive NMRD Stock Higher?

Regulatory approvals for sugarBEAT in new geographic markets.

• Strategic partnerships and collaborations with pharmaceutical companies or healthcare providers.
• Clinical trials demonstrating the efficacy and safety of sugarBEAT.
• Expansion of sales and marketing efforts to increase awareness of sugarBEAT.
• Development of new products and services to expand the company's portfolio.

What Are the Key Risks for NMRD?

Financial-distress signal — its Altman Z-Score of -23.47 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Competition from established players in the CGM market.
• Technological advancements by competitors.
• Changes in regulatory requirements.
• Limited financial resources.
• Reliance on regulatory approvals.

What Are the Growth Opportunities for NMRD?

• Expansion into new geographic markets: Nemaura Medical Inc. has the opportunity to expand its market reach by obtaining regulatory approvals for sugarBEAT in new geographic regions, such as Europe and Asia. These markets represent significant growth potential due to the large populations of individuals with diabetes and the increasing demand for CGM technology. Successful expansion into these markets could drive revenue growth and increase the company's global market share. The global CGM market is projected to reach $10 billion by 2028.
• Strategic partnerships and collaborations: Nemaura Medical Inc. can pursue strategic partnerships and collaborations with pharmaceutical companies, healthcare providers, and diabetes management organizations to expand its reach and accelerate the adoption of sugarBEAT. These partnerships could provide access to new distribution channels, patient populations, and clinical expertise. Collaborations with pharmaceutical companies could also lead to the development of integrated diabetes management solutions that combine sugarBEAT with drug therapies.
• Development of new products and services: Nemaura Medical Inc. can invest in the development of new products and services to expand its portfolio and address unmet needs in the diabetes management market. This could include developing new versions of sugarBEAT with enhanced features, such as improved accuracy, longer sensor life, and integration with mobile health apps. The company could also develop new services, such as remote patient monitoring and telehealth consultations, to provide comprehensive diabetes management support.
• Increased awareness and education: Nemaura Medical Inc. can invest in marketing and education initiatives to increase awareness of sugarBEAT and its benefits among patients and healthcare providers. This could include conducting clinical trials to demonstrate the efficacy and safety of sugarBEAT, publishing research papers in peer-reviewed journals, and participating in industry conferences and events. Increased awareness and education could drive adoption of sugarBEAT and increase the company's market share.
• Focus on pre-diabetes market: Nemaura Medical Inc. can focus on expanding its reach in the pre-diabetes market by promoting sugarBEAT as a screening tool for identifying individuals at risk of developing diabetes. The pre-diabetes market represents a significant growth opportunity due to the large number of individuals with pre-diabetes and the increasing awareness of the importance of early detection and intervention. By targeting the pre-diabetes market, Nemaura Medical Inc. can help prevent the progression of diabetes and improve the health outcomes of individuals at risk.

What Are NMRD's Competitive Advantages?

• Proprietary non-invasive CGM technology.
• Established brand reputation in the non-invasive glucose monitoring market.
• Strong relationships with healthcare providers and diabetes management organizations.
• Intellectual property protection for sugarBEAT technology.

What Does NMRD Do?

Nemaura Medical Inc., established in 2009 and headquartered in New York, is a medical technology company specializing in the development and manufacturing of continuous glucose monitoring (CGM) systems. The company's flagship product, sugarBEAT, is a non-invasive CGM device designed for use by individuals with Type I and Type II diabetes, as well as for screening pre-diabetic patients. Unlike traditional CGM systems that require inserting a sensor under the skin, sugarBEAT utilizes a skin patch to measure glucose levels non-invasively. In addition to sugarBEAT, Nemaura Medical offers proBEAT, a wellness guidance program that provides users with personalized insights and education on factors affecting their blood sugar profiles. This program aims to empower users to make informed lifestyle choices and manage their blood sugar levels effectively. Nemaura also conducts diabetes prevention and reversal programs, further expanding its reach in the diabetes management market. The company's focus on non-invasive technology and comprehensive diabetes management solutions positions it as a player in the evolving healthcare landscape.

What Products and Services Does NMRD Offer?

• Develop and manufacture non-invasive continuous glucose monitoring (CGM) systems.
• Offer sugarBEAT, a non-invasive CGM device for individuals with diabetes and pre-diabetes.
• Provide proBEAT, a wellness guidance program for managing blood sugar levels.
• Conduct diabetes prevention and reversal programs.
• Focus on providing painless and convenient glucose monitoring solutions.
• Target individuals with Type I and Type II diabetes, as well as pre-diabetic patients.

How Does NMRD Make Money?

• Sales of sugarBEAT CGM devices and related accessories.
• Subscription fees for the proBEAT wellness guidance program.
• Revenue from diabetes prevention and reversal programs.
• Partnerships with healthcare providers and diabetes management organizations.

What Industry Does NMRD Operate In?

The medical device industry is experiencing growth, driven by technological advancements and an aging global population. The market for continuous glucose monitoring (CGM) systems is particularly expanding due to the rising prevalence of diabetes and the increasing adoption of CGM technology for diabetes management. Nemaura Medical Inc. operates in this competitive landscape, facing competition from established players like Abbott and Dexcom, as well as emerging companies developing innovative CGM solutions. The company's focus on non-invasive technology differentiates it in the market, offering a potential advantage in attracting patients seeking a more convenient and painless monitoring experience.

Who Are NMRD's Key Customers?

• Individuals with Type I diabetes.
• Individuals with Type II diabetes.
• Pre-diabetic patients.
• Healthcare providers.
• Diabetes management organizations.

The most recent 10 insider filings for Nemaura Medical Inc. break down as 1 sales and 9 purchases. On net that is roughly 49.9M shares acquired (about $173K) — insiders putting money in tends to read as conviction.

Return on equity for Nemaura Medical Inc. stands at 249.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -97.1%, showing how much profit it generates from its asset base. A current ratio of 0.61 means current liabilities exceed short-term assets, a liquidity point worth watching.

Nemaura Medical Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -23.47 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Nemaura Medical Inc. revenue of about $3.4M for fiscal 2026, with EPS near $-0.34.

Company Profile

Nemaura Medical Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Dewan Fazlul Hoque Chowdhury. NMRD has traded publicly since 2018.

NMRD Financials

NMRD Latest News

NMRD Analyst Consensus

NMRD MoonshotScore

Nemaura Medical Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources